Prostate Cancer Survivorship: Prevention and Treatment of the Adverse Effects of Androgen Deprivation Therapy
Open Access
- 18 October 2009
- journal article
- review article
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 24 (S2) , 389-394
- https://doi.org/10.1007/s11606-009-0968-y
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31Journal of Clinical Oncology, 2009
- Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate CancerJAMA, 2008
- Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancerCancer, 2008
- FRAX™ and the assessment of fracture probability in men and women from the UKOsteoporosis International, 2008
- Adipocytokines, Obesity, and Insulin Resistance During Combined Androgen Blockade for Prostate CancerUrology, 2008
- Toremifene Increases Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase 3 Clinical StudyJournal of Urology, 2008
- Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate CancerJournal of Clinical Oncology, 2007
- The rising prevalence of androgen deprivation among older American men since the advent of prostate‐specific antigen testing: a population‐based cohort studyBJU International, 2006
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Noncancer Deaths in White Adult Cancer PatientsJNCI Journal of the National Cancer Institute, 1993